Table 2 Estimates of overall and weekly change from baseline in IDSIQ total score and treatment difference between daridorexant 50 mg versus placebo

Daridorexant 50 mg

N = 310

Placebo

N = 310

Daridorexant 50 mg vs. Placebo

Observed baseline mean (SD)

74.5 (25.16)

73.6 (24.64)

–

Change from baseline mean estimate (95% CI)

Change from baseline mean estimate (95% CI)

Treatment difference mean estimate (95% CI)

P-value

Overall

–15.2 (–17.0, –13.4)

–8.6 (–10.4, –6.9)

–6.6 (–9.1, –4.1)

< 0.0001

Week 1

–6.6 (–8.0, –5.3)

–2.7 (–4.1, –1.4)

–3.9 (–5.8, –1.9)

< 0.0001

Week 2

–10.2 (–11.8, –8.6)

–5.1 (–6.7, –3.5)

–5.1 (–7.4, –2.8)

< 0.0001

Week 3

–12.3 (–14.1, –10.6)

–5.6 (–7.3, –3.8)

–6.8 (–9.2, –4.3)

< 0.0001

Week 4

–13.6 (–15.4, –11.7)

–6.5 (–8.4, –4.7)

–7.1 (–9.7, –4.5)

< 0.0001

Week 5

–15.8 (–17.8, –13.9)

–8.5 (–10.4, –6.6)

–7.4 (–10.1, –4.6)

< 0.0001

Week 6

–16.3 (–18.4, –14.3)

–9.4 (–11.5, –7.4)

–6.9 (–9.8, –4.0)

< 0.0001

Week 7

–16.3 (–18.4, –14.2)

–10.1 (–12.2, –8.0)

–6.2 (–9.2, –3.3)

< 0.0001

Week 8

–16.8 (–18.9, –14.7)

–10.1 (–12.2, –8.0)

–6.7 (–9.7, –3.7)

< 0.0001

Week 9

–17.8 (–19.9, –15.6)

–11.1 (–13.3, –9.0)

–6.6 (–9.7, –3.6)

< 0.0001

Week 10

–18.6 (–20.8, –16.4)

–10.8 (–13.0, –8.6)

–7.9 (–11.0, –4.8)

< 0.0001

Week 11

–18.4 (–20.7, –16.1)

–11.5 (–13.8, –9.2)

–6.9 (–10.2, –3.7)

< 0.0001

Week 12

–19.5 (–21.8, –17.1)

–12.1 (–14.5, –9.7)

–7.4 (–10.7, –4.0)

< 0.0001